阳性和阴性症状量表（PANSS）培训：挑战、解决方案及未来方向
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions.
作者信息
Opler Mark G A, Yavorsky Christian, Daniel David G
机构信息
Dr. Opler is Adjunct Assistant Professor at NYU School of Medicine and Chief Research Officer at MedAvante-ProPhase Inc. in New York, New York.
Dr. Yavorsky is Chief Scientific Officer and Clinical Director at Cronos Clinical Consulting in Lambertville, New Jersey.
出版信息
Innov Clin Neurosci. 2017 Dec 1;14(11-12):77-81.
Abstract
Rater training and the maintenance of the consistency of ratings are critical to ensuring reliability of study measures and sensitivity to changes in the course of a clinical trial. The Positive and Negative Syndrome Scale (PANSS) has been widely used in clinical trials of schizophrenia and other disorders and is considered the "gold standard" for assessment of antipsychotic treatment efficacy. The various features associated with training and calibration of this scale are complex, reflecting the intricacy and heterogeneity of the disorders that the PANSS is used to evaluate. In this article, the authors review the methods for ensuring reliability of the PANSS as well as a proposed trajectory for its use in the future. An overview of the current principles, implementation, technologies, and strategies for the best use of the PANSS; tips for how to achieve consistency among raters; and optimal training practices of this instrument are presented.
摘要
评分者培训以及评分一致性的维持对于确保研究测量的可靠性和对临床试验过程中变化的敏感性至关重要。阳性和阴性症状量表（PANSS）已广泛应用于精神分裂症和其他疾病的临床试验，被视为评估抗精神病药物治疗疗效的“金标准”。与该量表的培训和校准相关的各种特征很复杂，反映了PANSS用于评估的疾病的复杂性和异质性。在本文中，作者回顾了确保PANSS可靠性的方法以及其未来使用的建议轨迹。介绍了当前最佳使用PANSS的原则、实施、技术和策略概述；评分者之间达成一致性的技巧；以及该工具的最佳培训实践。
相似文献
1
Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions.阳性和阴性症状量表（PANSS）培训：挑战、解决方案及未来方向
Innov Clin Neurosci. 2017 Dec 1;14(11-12):77-81.
2
Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS).阳性和阴性症状量表（PANSS）标准化评估者培训的评估
Schizophr Res. 1998 Aug 17;32(3):151-60. doi: 10.1016/s0920-9964(98)00051-6.
3
Inter-rater reliability of ratings on the six-item Positive and Negative Syndrome Scale (PANSS-6) obtained using the Simplified Negative and Positive Symptoms Interview (SNAPSI).使用简化正负症状访谈（SNAPSI）获得的六项阳性和阴性症状量表（PANSS-6）评分的评分者间信度。
Nord J Psychiatry. 2018 Aug;72(6):431-436. doi: 10.1080/08039488.2018.1492014. Epub 2018 Jul 24.
4
Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6).六项目阳性和阴性症状量表（PANSS-6）评定的标准化培训。
Schizophr Res. 2021 Feb;228:438-446. doi: 10.1016/j.schres.2020.12.044. Epub 2021 Feb 9.
5
Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).评估一项失败的临床试验中不可靠的来源（评估者、受试者、时间点），使用阳性和阴性症状量表（PANSS）的项目。
J Clin Psychopharmacol. 2013 Feb;33(1):109-17. doi: 10.1097/JCP.0b013e3182776ebe.
6
Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.简明阳性和阴性症状量表（PANSS）的简化版本可行吗？一项批判性综述。
Innov Clin Neurosci. 2017 Dec 1;14(11-12):73-76.
7
[Evaluation of standardized training for the "Positive and Negative Syndrome Scale" (PANSS)].["阳性和阴性症状量表"（PANSS）标准化培训评估]
Nervenarzt. 2000 Mar;71(3):195-204. doi: 10.1007/s001150050029.
8
Interrater reliability of the Structured Clinical Interview for the Positive and Negative Syndrome Scale for schizophrenia.精神分裂症阳性和阴性症状量表结构化临床访谈的评分者间信度。
Acta Psychiatr Scand. 1994 Mar;89(3):192-5. doi: 10.1111/j.1600-0447.1994.tb08091.x.
9
Validity and Reliability of the Arabic Version of the Positive and Negative Syndrome Scale.阳性和阴性症状量表阿拉伯语版本的效度与信度
Psychopathology. 2016;49(3):181-7. doi: 10.1159/000447328. Epub 2016 Jul 30.
10
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.精神分裂症急性症状患者中临床医生评定的个人和社会表现量表的信度、效度及检测变化的能力。
Curr Med Res Opin. 2009 Feb;25(2):325-38. doi: 10.1185/03007990802611919.
引用本文的文献
1
Multidisciplinary approach to matricide and post-mortem cannibalism: Integrating medico-legal and psychiatric investigations.弑母与死后食人行为的多学科研究方法：整合法医学与精神病学调查
Forensic Sci Int Synerg. 2025 Jun 24;11:100615. doi: 10.1016/j.fsisyn.2025.100615. eCollection 2025 Dec.
2
Navigating Adversity: Ethnoracial Discrimination, Family Support, and Psychotic Symptom Severity in US Latinx People with First Episode Psychosis.应对逆境：美国首次发作精神病的拉丁裔人群中的种族歧视、家庭支持与精神病症状严重程度
J Racial Ethn Health Disparities. 2025 Feb 27. doi: 10.1007/s40615-025-02308-w.
3
Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia.由药剂师主导的精神分裂症关怀（Si-care）模式，以提高精神分裂症患者的药物依从性和症状管理水平。
Explor Res Clin Soc Pharm. 2024 Nov 22;16:100544. doi: 10.1016/j.rcsop.2024.100544. eCollection 2024 Dec.
4
Correlates of adverse childhood experiences among admitted patients with schizophrenia in a referral psychiatric hospital in Botswana.博茨瓦纳一家转诊精神病医院收治的精神分裂症患者童年不良经历的相关因素
Int J Soc Psychiatry. 2025 Mar;71(2):338-348. doi: 10.1177/00207640241291500. Epub 2024 Nov 25.
5
Magnetic resonance imaging-based machine learning classification of schizophrenia spectrum disorders: a meta-analysis.基于磁共振成像的精神分裂症谱系障碍机器学习分类：一项荟萃分析。
Psychiatry Clin Neurosci. 2024 Dec;78(12):732-743. doi: 10.1111/pcn.13736. Epub 2024 Sep 18.
6
Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers.基于药物基因组学的精神分裂症管理：一项混合 2 型有效性实施研究方案，旨在比较临床实用性、成本效益和障碍。
PLoS One. 2024 Apr 10;19(4):e0300511. doi: 10.1371/journal.pone.0300511. eCollection 2024.
7
The Implications of Cytochrome P450 2D6/CYP2D6 Polymorphism in the Therapeutic Response of Atypical Antipsychotics in Adolescents with Psychosis-A Prospective Study.细胞色素P450 2D6/CYP2D6基因多态性对青少年精神病患者非典型抗精神病药物治疗反应的影响——一项前瞻性研究
Biomedicines. 2024 Feb 22;12(3):494. doi: 10.3390/biomedicines12030494.
8
Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.应对中枢神经系统临床试验中安慰剂反应挑战的现有及新兴技术：前景、陷阱与未来之路
Innov Clin Neurosci. 2024 Mar 1;21(1-3):19-30. eCollection 2024 Jan-Mar.
9
The role of glial cells in mental illness: a systematic review on astroglia and microglia as potential players in schizophrenia and its cognitive and emotional aspects.神经胶质细胞在精神疾病中的作用：关于星形胶质细胞和小胶质细胞作为精神分裂症及其认知和情感方面潜在参与者的系统综述。
Front Cell Neurosci. 2024 Feb 14;18:1358450. doi: 10.3389/fncel.2024.1358450. eCollection 2024.
10
A Study of Neurological Soft Signs and Cognition in Schizophrenia.精神分裂症的神经软体征与认知研究
Cureus. 2023 Dec 21;15(12):e50925. doi: 10.7759/cureus.50925. eCollection 2023 Dec.
本文引用的文献
1
Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS).一致性检验可提高阳性与阴性症状量表（PANSS）的测量效果。
Schizophr Res. 2017 Dec;190:74-76. doi: 10.1016/j.schres.2017.03.017. Epub 2017 Mar 9.
2
Rater Training for a Multi-Site, International Clinical Trial: What Mood Symptoms may be most Difficult to Rate?多中心国际临床试验的评估者培训：哪些情绪症状可能最难评估？
Psychopharmacol Bull. 2011 Sep 15;44(3):5-14.
3
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders.临床试验中的数据质量监测：是否值得？所有利益相关者对未来的评估与预测。
Innov Clin Neurosci. 2016 Feb 1;13(1-2):27-33. eCollection 2016 Jan-Feb.
4
The feasibility of using electronic clinical outcome assessments in people with schizophrenia and their informal caregivers.在精神分裂症患者及其非正式照料者中使用电子临床结局评估的可行性。
Patient Relat Outcome Meas. 2015 Mar 26;6:91-101. doi: 10.2147/PROM.S79348. eCollection 2015.
5
Explanatory models and concepts of West African Malian patients with psychotic symptoms.西非马里精神病患者的解释模型和概念。
Eur Psychiatry. 2012 Jun;27 Suppl 2:S44-9. doi: 10.1016/S0924-9338(12)75707-3.
6
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?精神分裂症临床试验中的安慰剂相关效应：是什么驱动了这一现象，以及可以采取什么措施将其最小化？
Int J Neuropsychopharmacol. 2012 Aug;15(7):1003-14. doi: 10.1017/S1461145711001738. Epub 2012 Jan 5.
7
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.在一项针对精神分裂症的多中心临床试验中，通过实时双向视频使用远程集中评估者。
J Clin Psychopharmacol. 2008 Dec;28(6):691-3. doi: 10.1097/JCP.0b013e31818c9ba3.
8
PANSS rater training using Internet and videoconference: results from a pilot study.使用互联网和视频会议进行的阳性和阴性症状量表（PANSS）评分员培训：一项试点研究的结果
Schizophr Res. 2007 May;92(1-3):63-7. doi: 10.1016/j.schres.2007.01.011. Epub 2007 Mar 1.
9
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.阳性和阴性症状量表的五因素模型I：验证性因素分析未能证实25种已发表的五因素解决方案。
Schizophr Res. 2006 Jul;85(1-3):273-9. doi: 10.1016/j.schres.2006.04.001. Epub 2006 May 26.
10
What does the PANSS mean?PANSS是什么意思？
Schizophr Res. 2005 Nov 15;79(2-3):231-8. doi: 10.1016/j.schres.2005.04.008. Epub 2005 Jun 27.
Zotero 插件